Your browser doesn't support javascript.
loading
Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format.
Mannhardt, Ingra; Saleem, Umber; Mosqueira, Diogo; Loos, Malte F; Ulmer, Bärbel M; Lemoine, Marc D; Larsson, Camilla; Améen, Caroline; de Korte, Tessa; Vlaming, Maria L H; Harris, Kate; Clements, Peter; Denning, Chris; Hansen, Arne; Eschenhagen, Thomas.
Afiliação
  • Mannhardt I; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany. Electronic address: i.mannhardt@uke.de.
  • Saleem U; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
  • Mosqueira D; Division of Cancer & Stem Cells, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
  • Loos MF; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
  • Ulmer BM; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
  • Lemoine MD; Department of Cardiology-Electrophysiology, University Heart Center, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
  • Larsson C; Takara Bio Europe AB, 41346 Göteborg, Sweden.
  • Améen C; Takara Bio Europe AB, 41346 Göteborg, Sweden.
  • de Korte T; Ncardia, 2333 BD Leiden, the Netherlands; Department of Anatomy and Embryology, Leiden University Medical Center, 2333 ZD Leiden, The Netherlands.
  • Vlaming MLH; Ncardia, 2333 BD Leiden, the Netherlands.
  • Harris K; GlaxoSmithKline, David Jack Centre for R&D, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
  • Clements P; GlaxoSmithKline, David Jack Centre for R&D, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
  • Denning C; Division of Cancer & Stem Cells, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
  • Hansen A; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
  • Eschenhagen T; Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany. Electronic address: t.eschenhagen@uke.de.
Stem Cell Reports ; 15(4): 983-998, 2020 10 13.
Article em En | MEDLINE | ID: mdl-33053362
ABSTRACT
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially available, and cardiac differentiation established routine. Systematic evaluation of several control hiPSC-CM is lacking. We investigated 10 different control hiPSC-CM lines and analyzed function and suitability for drug screening. Five commercial and 5 academic hPSC-CM lines were casted in engineered heart tissue (EHT) format. Spontaneous and stimulated EHT contractions were analyzed, and 7 inotropic indicator compounds investigated on 8 cell lines. Baseline contractile force, kinetics, and rate varied widely among the different lines (e.g., relaxation time range 118-471 ms). In contrast, the qualitative correctness of responses to BayK-8644, nifedipine, EMD-57033, isoprenaline, and digoxin in terms of force and kinetics varied only between 80% and 93%. Large baseline differences between control cell lines support the request for isogenic controls in disease modeling. Variability appears less relevant for drug screening but needs to be considered, arguing for studies with more than one line.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Engenharia Tecidual / Avaliação Pré-Clínica de Medicamentos / Células-Tronco Pluripotentes Induzidas / Coração Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Engenharia Tecidual / Avaliação Pré-Clínica de Medicamentos / Células-Tronco Pluripotentes Induzidas / Coração Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article